Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec
NEW YORK, March 2, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Sunshine Heart (NASDAQ: SSH), Synergetics USA (NASDAQ: SURG), Syneron Medical (NASDAQ: ELOS), Spectranetics (NASDAQ: SPNC), and Thoratec (NASDAQ: THOR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
SSH Research Report: ( http://get.analystsreview.com/pdf/?c=Sunshine%20Heart&d=02-Mar-2015&s=SSH ),
SURG Research Report: ( http://get.analystsreview.com/pdf/?c=Synergetics%20USA&d=02-Mar-2015&s=SURG ),
ELOS Research Report: ( http://get.analystsreview.com/pdf/?c=Syneron%20Medical&d=02-Mar-2015&s=ELOS ),
SPNC Research Report: ( http://get.analystsreview.com/pdf/?c=Spectranetics&d=02-Mar-2015&s=SPNC ),
THOR Research Report: ( http://get.analystsreview.com/pdf/?c=Thoratec&d=02-Mar-2015&s=THOR ).
============
--
Analyst Update: Loan Agreements and Financial Results
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks ended February with their biggest monthly percentage gains in more than two years. In February, the Dow Jones Industrial Average jumped 5.64%, its best month since January 2013. However on Friday, The Dow Jones Industrial Average fell 81.72 points, or 0.45%, to 18132.70. The S&P 500 slipped 6.24 points, or 0.30%, to 2104.50 and the Nasdaq Composite declined 24.36 points, or 0.49%, to 4963.53. The Commerce Department reported that U.S. gross domestic product expanded at a 2.2% annual rate in the fourth quarter, down from an initial estimate of 2.6%. Separately, the Chicago Business Barometer fell to its lowest point since July 2009, declining to 45.8 in February from January's 59.4. European markets mostly closed higher. Asia Pacific share market ended mixed, on tracking weak lead from Wall Street overnight. China share market finished higher in volatile trade, with investors looking ahead to the annual sessions of China's two key legislative bodies next week. Moreover on Saturday, China reduced its benchmark interest rate by 25 basis points to 5.35% along with a 25 basis point cut in the benchmark saving rate to 2.5%, effective from Sunday.
On February 18, 2015, Sunshine Heart Inc. (Sunshine Heart) entered into a loan and security agreement with Silicon Valley Bank to secure up to $10.0 million in growth capital. The loan, with a maturity date of December 1, 2017, will be used for general corporate and working capital purposes.
Synergetics USA, Inc. (Synergetics USA) posted growth in both its primary businesses as well as in both the U.S. and International markets in Q1 FY15. Total sales increased 7.2% YoY to $16.6 million during the quarter, driven primarily by a 12.2% YoY increase in OEM sales and a 2.7% YoY increase in Ophthalmic sales.
Syneron Medical Ltd. (Syneron Medical) reported its strongest quarter ever with record fourth quarter 2014 revenue of $74.1 million, up 23.7% YoY. The quarter witnessed robust growth in North American product revenue, driven by the commercial launch of UltraShape in the U.S. and the global PicoWay launch.
The Spectranetics Corporation (Spectranetics) achieved revenue growth of 50% YoY during the fourth quarter of 2014. However, the Company reported a net loss for the period, compared to net income in the prior year period. The Company also updated its outlook for 2015 to reflect the projected impact of Stellarex and adjustments for the weakening euro.
Thoratec Corporation (Thoratec) reported better-than-expected results for the fourth quarter of 2014. Fourth-quarter product sales/revenue of $128 million beat the Zacks Consensus Estimate of $106 million.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article